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Cutting Edge: The Heat Shock Protein gp96 Activates
Inflammasome-Signaling Platforms in APCs
Yifei Wang,*,† Abigail L. Sedlacek,† Sudesh Pawaria,‡ Haiyan Xu,x
Melanie J. Scott,{ and Robert J. Binder†
Several heat shock proteins (HSPs) prime immune re-
sponses, which are, in part, a result of activation of
APCs. APCs respond to these immunogenic HSPs
by upregulating costimulatory molecules and secreting
cytokines, including IL-1b. These HSP-mediated
responses are central mediators in pathological
conditions ranging from cancer, sterile inflammation
associated with trauma, and rheumatoid arthritis. We
tested in this study the requirement of inflammasomes
in the release of IL-1b by one immunogenic HSP,
gp96. Our results show that murine APCs activate
NLRP3 inflammasomes in response to gp96 by K+
efflux. This is shown to initiate inflammatory condi-
tions in vivo in the absence of additional known
inflammasome activators or infection. These results
document a novel mechanism by which proteins of
endogenous origin, the HSPs, can modulate an inflam-
matory response following their release from aberrant
cells. The Journal of Immunology, 2018, 201: 2209–
2214.
I
mmunization of mice and humans with select heat shock
proteins (HSPs) initiates a program of inflammation
characterized by the release of IL-1b, IL-6, and TNF-a
from APCs (1, 2). These cytokines are partially responsible
for eliciting Th1 responses (1); the other components being
upregulation of costimulation by the APC (2) and cross-
presentation of HSP-chaperoned peptides (3). Although
there has been a great interest in harnessing these Th1 re-
sponses for the immunotherapy of cancer and infectious
disease (4), the complexities of cytokine release by APCs have
not yet been fully investigated. Importantly, the distinct sig-
naling pathways and final repertoire of cytokines released is
dependent on the APC that is engaged by the HSP (1, 2, 5, 6)
and the contribution of other signals in the microenviron-
ment (1). These mechanisms allow HSPs to prime Th1 (3),
Th17 (1), or regulatory T cell responses (6, 7). The release
of IL-1b from a variety of APCs, including dendritic cells
(DCs) and macrophages, in response to HSPs, has conspic-
uously lacked a basic characterization even though this
seminal observation was made over 17 y ago (2). Although
the predominant mechanism for IL-1b maturation and
release from cells requires the activation of inflammasomes
(8), several inflammasome-independent pathways have been
described (9).
The inflammasome is a central component of the innate
immune system geared toward recognizing changes in cellular
homeostasis and generating responses for clearing pathogens
and for tissue repair. As a multimeric protein complex, it is
responsible for activation of caspase-1, which proceeds to
cleave multiple substrates, including pro–IL-1b and pro–IL-
18, into their mature form (8).
We show that the prototypical immunogenic HSP, gp96,
initiates two signals in APCs: 1) an NF-kB and p38-dependent
upregulation in the synthesis of pro–IL-1b, and 2) activation
of the NLRP3 inflammasome itself. The release of HSPs into
the extracellular environment, in the absence of obvious in-
fection or pathogens, is a molecular trigger for inflamma-
tion and is relevant for conditions ranging from sterile
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Peritoneal exudate cells (PECs) were collected from the peritoneal cavity
of mice with PBS and cultured overnight in RPMI 1640 complete me-
dium (5% FBS) to obtain the adherent population. DCs were differ-
entiated from mouse bone marrow cells for 6 d with 0.02 mg/ml GM-CSF
(added on days 0 and 3). B16 (containing empty plasmid) and B16/
gp96 cells were cultured in complete DMEM medium (10% FBS) with
0.4 g/l G418.
Reagents and inhibitors
Gp96 was purified from mouse livers and verified by SDS-PAGE and im-
munoblotting (2). Endotoxin contamination is determined to be below the
detection limit of the Limulus amebocyte lysate (2). One nanogram of LPS
(Sigma-Aldrich) is equivalent to 5 endotoxin units (Limulus amebocyte lysate
assay) or 10 endotoxin units (chromogenic assay). Where indicated, PECs
were treated with 10 mM of nigericin (Tocris Bioscience), 10 mM of the
NF-kB inhibitor cardamonin (Sigma-Aldrich), 15 mM of the p38 MAPK
inhibitor SB203580 (Calbiochem), 20 mg/ml caspase-1 inhibitor YVAD
(Calbiochem), 2 mM of the reactive oxygen species (ROS) scavenger
N-acetylcysteine (MP Biomedicals), or 25 mM of the P2X7 inhibitor A438079
(Tocris Bioscience). N-Acetylcysteine and A438079 were verified to block
IL-1b production by PECs treated with LPS plus ATP (data not shown).
Treatments started 30 min prior and lasted for the duration of the experi-
ment. Cell lysates were analyzed by SDS-PAGE and immunoblotting with
primary and HRP-conjugated secondary Abs. Primary Abs to pro–IL-1b,
NLRP3, ASC, and b-Actin were from Cell Signaling Technology, and to
caspase-1 (p20) were from AdipoGen Life Sciences. The FLICA assay was
performed using FAM FLICA Caspase-1 Kit (Bio-Rad Laboratories). The
APC Annexin V Apoptosis Detection Kit (BioLegend) was used for the cell
death experiments.
Procedures
ASC oligomerization was performed according to Katsnelson et al.
(12). IL-1b was measured by ELISA (Thermo Fisher Scientific). Blood
was collected from orbital sinus of mice, and serum was harvested by
centrifugation.
Flow cytometry
Mice were injected with 2 3 106 B16 or B16/gp96 cells i.p. After 8 or 18 h,
PECs were harvested and fixed/permeabilized (BD Biosciences), followed by
staining with Abs; F4/80 (PerCP-Cy5.5), pro–IL-1b (APC), and anti-mouse
IgG (FITC) were from eBioscience, CD11b (PE-Cy7) and Ly-6G (PE) from
BD Biosciences, and CD91 from Abcam. Data acquisition was performed
with BD LSR II or BD LSRFortessa instruments and analyzed using FlowJo.
Data acquired by the Amnis ImageStream (ImageStream Mark II) were
analyzed with IDEAS 6.2.
Statistical analyses
Statistical analyses were performed with Prism Software using ANOVA or two-
tailed t test for comparison between two variables. Statistical significance was
defined as *p, 0.05, **p, 0.01, ***p, 0.001, and ****p, 0.0001. Graphs
are mean 6 SD.
FIGURE 1. Gp96 induces synthesis of pro–IL-1b in a CD91-dependent manner. (A and B) PECs were treated with gp96 at the indicated concentration or
PBS. Cell lysates were analyzed for pro–IL-1b protein by SDS-PAGE and immunoblotting at 4 h (A) or over a time period from 0 to 20 h (B). (C) PECs were
pretreated with cardamonin, SB203580, or DMSO, followed by incubation with 200 mg/ml gp96 or 10 mg/ml LPS or PBS. Pro–IL-1b protein level was
measured as in (A). (D) DCs from CD91fl/fl or CD91fl/flCD11cCre mice were treated with 200 mg/ml gp96 or 10 mg/ml LPS or PBS for 4 h. Pro–IL-1b was
analyzed as in (A). In (A)–(D), the amount of pro–IL-1b was quantified and normalized to actin as a loading control. In (A), comparisons are made to PBS-treated
cells. (E–G) B16 or B16/gp96 cells were implanted into the peritoneal cavity of mice. PECs were harvested after 8 or 18 h and analyzed by flow cytometry with
gating on macrophages (F4/80) and CD91 and further on intracellular pro–IL-1b (E). Gray filled histogram is Ab isotype staining. Mean fluorescence intensity
(MFI) from the histograms are presented in (F). (G) PECs were further analyzed with markers for neutrophils (Ly6G). Data are from one representative
experiment of three to five independent experiments. **p , 0.01, ***p , 0.001.
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The immunogenic HSP gp96 upregulates expression of pro–IL-1b
in macrophages
As a substrate for inflammasome activity, we probed for the
expression of pro–IL-1b in murine-isolated, adherent PECs
in response to gp96. PECs were pulsed with a dose range of
mouse tissue–derived gp96. Cells were harvested after 4 h,
lysed, and probed by immunoblotting with Abs specific to
pro–IL-1b or actin as a loading control. The lower threshold
of gp96 for induction of pro–IL-1b was between 0.1 and 1
mg/ml, reaching maximal induction at 10 mg/ml (Fig. 1A)
(there is no statistical difference between 10 and 200 mg/ml).
With 10 or 200 mg/ml gp96, pro–IL-b induction peaked at
4 h following stimulation with gp96 (Fig. 1B, Supplemental
Fig. 1A). We postulated that the taper after 4 h was, in part,
due to conversion of pro–IL-1b into IL-1b; upon which,
recognition by the pro–IL-1b–specific immunoblotting Ab
is lost. Alternatively, this could be due to the IL-10–driven
negative feedback loop that shuts down the pro–IL-1b
transcription induced by inflammatory signals (13). We used
LPS, a known stimulator of pro–IL-1b, as a positive control
(8). Pro–IL-1b induction with LPS peaked later than with
gp96, consistent with earlier observations on kinetics of
signaling induced by the two molecules (1, 2). Signaling via
CD91, induced with gp96, is known to activate NF-kB and
p38 MAPK (1), and we tested their role in the induction
of pro–IL-1b. PECs were incubated with gp96 in the pres-
ence or absence of cardamonin or SB203580, inhibitors
of NF-kB or p38 MAPK, respectively (1, 14). Pro–IL-1b
was measured by immunoblotting. Pro–IL-1b induction
was significantly impaired with either inhibitor (Fig. 1C,
Supplemental Fig. 1B). Similar results were obtained with
DCs (Supplemental Fig. 1C). To confirm CD91 depen-
dency and, importantly, to eliminate the possibility that
these observations were due to hypothetical contaminating
endotoxin in the gp96 preparations, we harvested DCs
from our novel CD91fl/flCD11cCre mice (10) and tested pro–
IL-1b synthesis. We show that in the absence of CD91
(CD91fl/flCD11cCre), APCs are unable to synthesize pro–
IL-1b when stimulated with gp96 (Fig. 1D). As expected,
these APCs make pro–IL-1b in response to LPS regardless of
CD91 expression, consistent with a TLR2/4-dependent
mechanism (15). These results are fully consistent with
CD91-dependent IL-1b production observed previously (10).
To test the induction of pro–Il-1b in vivo, we used an im-
plantable cellular gp96-secretory system (16). In this study,
B16 tumor cells express a gp96–Ig fusion construct (B16/
gp96); 1 3 106 cells secrete ∼300 ng of gp96 in 24 h (16).
B16/gp96 or parental B16 cells (with empty vector) were
implanted into the peritoneal cavity of mice, targeting the
same PECs we used in vitro. At 8 or 18 h posttumor im-
plantation, we analyzed pro–IL-1b in F4/80+CD91+ cells by
flow cytometry (Supplemental Fig. 1D). Significant amounts
of pro–IL-1b were produced at 8 h when B16/gp96 cells were
implanted, but not B16 cells (Fig. 1E, 1F). Pro–IL-1b con-
verted to mature IL-1b at 18 h (Fig. 1F). Next, we confirmed
that pro–IL-1b was being made by macrophages (20% of
total cells), which are the CD91+ cells in the peritoneal cavity
using the Amnis ImageStream. We show that 4.8% of total
cells are CD91+ and are synthesizing pro–IL-1b (Fig. 1G,
Supplemental Fig. 1E). Importantly, no neutrophils (0.0% of
Ly-6G+) make IL-1b.
Macrophages release IL-1b in response to extracellular gp96 in vivo
We examined the release of IL-1b by PECs in response to
gp96, following production of pro–IL-1b. PECs were stim-
ulated with 10 or 200 mg/ml gp96 (doses of gp96 at which
peak pro–IL-1b was produced) for 0–20 h. IL-1b was mea-
sured by ELISA. PECs were observed to continually release
IL-1b in response to gp96 (Fig. 2A). Release of IL-1b was
titratable with dose of gp96. We used our cellular, gp96-
secretory system in this study to examine IL-1b production
FIGURE 2. Macrophages release IL-1b in response to extracellular gp96
in vivo. (A) PECs were treated with different doses of gp96 or PBS in vitro.
Supernatants of the culture were harvested at indicated time points, and IL-
1b was measured by ELISA. (B) Macrophage (F4/80+Ly-6G2) and neutro-
phil (F4/802Ly-6G+) populations in peritoneal cavity of mice were analyzed
by flow cytometry 18 h after implantation of B16 or B16/gp96 or injection of
20 mg LPS. (C) Blood was collected from mice 8 h after i.p. injection of PBS,
B16, B16/gp96, or gp96 at the indicated dose or LPS. IL-1b in serum was
measured. (D) B16/gp96 (2 3 106), gp96 (50 mg), or LPS (20 mg) were
injected i.p., and cells were analyzed 8 h later for intracellular pro–IL-1b in
CD11b+ cells. *p , 0.05, **p , 0.01, ***p , 0.001.
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in vivo. The extravasation of neutrophils into the peritoneal
cavity is dependent on IL-1b (17). We examined changes in
immune infiltrate in response to extracellular gp96. Gp96,
secreted by B16/gp96 cells, induced the extravasation of
neutrophils into the peritoneal cavity 18 h after transplanta-
tion (Fig. 2B, Supplemental Fig. 1G). The increase in neu-
trophils was not observed when control B16 cells were
introduced, suggesting the observed neutrophil extravasation
was a gp96-mediated event rather than related to implanta-
tion of cells (Fig. 2B). The increase in the percentage of
neutrophils (2–25%) corresponded to a similar reduction in
the percentage of macrophages. Introduction of the bacterial
product LPS caused some changes in neutrophil, but not
macrophage, populations at 18 h, which is consistent with
previous reports (17). This provides a contrast in the cellular
dynamics and kinetics of inflammation induced with gp96
versus LPS (Fig. 2B). Next, we directly measured IL-1b in the
blood following extracellular localization of gp96, either se-
creted from cells or via i.p. injection. Mice were implanted
with B16 or B16/gp96 or injected with PBS, gp96, or LPS.
IL-1b was measured in serum 8 h later (Fig. 2C). The gp96
produced by B16/gp96 in this time was ∼200 ng. Serum IL-
1b was detected when B16/gp96 was implanted, but not B16.
Serum IL-1b was titratable with the dose of gp96 injected
(Fig. 2C). We compared gp96 secreted from B16/gp96 cells
with purified gp96 introduced via i.p. injection to confirm the
cellular source of IL-1b. PECs were harvested after 8 h and
analyzed with the Amnis ImageStream. Regardless of the
source of gp96, pro–IL-1b was produced by CD11b+ mac-
rophages (3–9% of total cells). LPS also induced pro–IL-1b
in macrophages (5% of total cells) as expected (Fig. 2D,
Supplemental Fig. 1F).
FIGURE 3. Gp96 activates inflammasomes for IL-1b release. (A and B) PECs were treated with PBS or gp96 at the indicated concentrations for 4 h (A) or over
time (B). NLRP3 was analyzed by SDS-PAGE and immunoblotting. (C) PECs were treated with cardamonin or SB203580, followed by incubation with 200 mg/ml
gp96 or DMSO. NLRP3 was analyzed as in (A). (D) PECs were treated with YVAD, followed by incubation with gp96 or PBS. IL-1b was measured as in (A)
after 4 h. (E and F) PECs were harvested from WT or NLRP32/2 mice and treated with 10 (F) or 200 mg/ml (E and F) gp96 or PBS for 4 h. (E) NLRP3 or pro–
IL-1b and ASC oligomerization were analyzed as in (A). PECs treated with a combination of LPS and nigericin as a positive control (E). IL-1b was measured by
ELISA (F). (G) Blood was collected from WT or NLRP32/2 mice 8 h after i.p. injection of gp96 (50 mg) or LPS (20 mg). IL-1b was measured in the serum by
ELISA. (H and I) PECs were treated with gp96 at the indicated dose or PBS for 4 h. The treated PECs were incubated for a further 30 min with nigericin or PBS.
IL-1b was measured in the culture supernatant (H), whereas cell lysates (I) were harvested and analyzed as in (A). (J and K) PECs were primed with 300 ng/ml
LPS for 3 h and then activated with gp96 for different times. (J) Cell lysate was collected, and cleaved caspase-1 (p20) was analyzed by immunoblotting. (K) IL-1b
concentration in supernatants was tested by ELISA. In panels (A), (B), (G), and (I), the amount of pro–IL-1b or NLRP3 or caspase-1 was quantified and
normalized to actin as a loading control. In (A) and (B), comparisons are made to PBS-treated cells. Data are from one representative experiment of three to five
independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001
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Gp96 simultaneously upregulates pro–IL-1b and components of
NLRP3 inflammasome
The main mechanism for conversion of pro–IL-1b to the
mature IL-1b requires inflammasome activation. In prepara-
tion for such activation, expression of various constituent
proteins are upregulated. We measured NLRP3 levels fol-
lowing treatment of cells with gp96. PECs were incubated
with titrated doses of gp96 for 4 h. Cells were lysed and
probed by immunoblotting for NLRP3. Induction of NLRP3
was observed with 1 mg/ml gp96, increasing with gp96 to
200 mg/ml (Fig. 3A, Supplemental Fig. 1H). The levels of
NLRP3 were sustained and stable for over 20 h following
stimulation with gp96 (Fig. 3B, Supplemental Fig. 1I), con-
sistent with its observed half-life in cells (18). We next tested
whether the induction of NLRP3 was dependent on NF-kB
and p38 MAPK. PECs were treated with gp96 in the presence
or absence of cardamonin or SB203580. In Fig. 3C and
Supplemental Fig. 1J, we show that NLRP3 induction by gp96
was dependent on NF-kB, but not p38 MAPK. These sig-
naling pathways are consistent with earlier observations (1, 6).
Release of IL-1b in response to gp96 is inflammasome dependent
We next tested the involvement of inflammasome constituents
in gp96-mediated IL-1b release. PECs were treated with the
caspase-1 inhibitor YVAD prior to, and for the duration of,
gp96 stimulation. YVAD was observed to inhibit the IL-1b
released in response to gp96 (Fig. 3D). We used the FAM-
YVAD-FMK fluorescent inhibitor probe to label active
caspase-1 enzyme in responding cells. A significant number of
macrophages responded to titratable amounts of gp96 by
activating caspase-1 (Supplemental Fig. 2A). Oligomerization
of the adaptor protein ASC is a key indicator of inflamma-
some activation (19). ASC oligomers were observed in PECs
stimulated with gp96 for 4 h (Fig. 3E). In the absence of the
sensor protein NLRP3 (in PECs from NLRP32/2 mice), no
ASC oligomerization was observed. As a positive control,
robust ASC oligomerization was observed when WT, but not
NLRP32/2 cells, were stimulated with 10 mg/ml LPS plus
10 mM of the synthetic antibiotic nigericin, known stimulators
of the inflammasome in macrophages (12) (Fig. 3E). We next
stimulated PECs from NLRP32/2 or WT mice with gp96.
IL-1b release by NLRP32/2 PECs in response to gp96 was
severely attenuated (Fig. 3F). We also tested whether serum
IL-1b, observed in response to injected gp96, was inflam-
masome dependent. WT or NLRP32/2 mice were injected
with gp96 (50 mg) or LPS (20 mg). Serum IL-1b was mea-
sured by ELISA (Fig. 3G). Results show that there is a sig-
nificant decline in IL-1b in the serum in the absence of
NLRP3. We compared the relative extent of inflammasome
activation by gp96, an endogenous protein, with nigericin,
which acts as a K+ ionophore (12). PECs were stimulated with
gp96 for 4 h, followed by a 30-min pulse with nigericin.
Nigericin overwhelmingly boosted the release of IL-1b
compared with PECs stimulated with gp96 alone (Fig. 3H).
The increased release of IL-1b induced by gp96 plus nigericin
led to a corresponding decrease in the inflammasome sub-
strate pro–IL-1b (Fig. 3I, Supplemental Fig. 2B). To confirm
that gp96 could activate inflammasomes, cells were primed
with LPS for 3 h and then stimulated with gp96 over a
timecourse. Cells treated with this regimen activated caspase-1
(Fig. 3J, Supplemental Fig. 2C) and released IL-1b (Fig. 3K).
Inflammasome activation by gp96 requires K+ efflux, but not ROS
production or P2X7
To understand how gp96 was activating the inflammasome, we
stimulated PECs with gp96 in the presence or absence of
inhibitors to K+ efflux, ROS, and P2X7. IL-1b production was
measured after 4 h. KCl in the medium, which inhibits K+
efflux from cells, abrogated the production of IL-1b in-
duced by gp96 by inhibiting inflammasomes as measured by
caspase-1 activation (Fig. 4A, 4B). At the same molarity,
NaCl had no effect on IL-1b production induced by
gp96. However, inhibition of ROS production with
N-acetylcysteine (Fig. 4C) or blocking the ATP receptor P2X7
with A438079, which is one way of mediating K+ efflux after
extracellular ATP binding, had no effect on IL-1b production
(Fig. 4D). Interestingly, CD91 was recently shown to directly
associate with Ca2+-activated K+ channels and modulate this
channel to the open state upon binding to one of its non-HSP
ligands, a2-macroglobulin (20). This could provide a direct
mechanism through which CD91 drives a decline in intra-
cellular K+ concentrations, thereby activating inflammasomes.
This is consistent with our observation that activation of
FIGURE 4. Gp96 activates inflammasome via K+ ef-
flux. (A–D) PECs were treated with 200 mg/ml gp96 or
PBS in the presence or absence of (A and B) 20 mM KCl
or NaCl, (C) 2 mM N-acetylcysteine, or (D) 25 mM
A438079. IL-1b in culture supernatants was measured
(A, C, and D), and cell lysates were harvested and ana-
lyzed for caspase-1 (p20) by SDS-PAGE and immuno-
blotting (B) after 4 h. (E) WT or GD2/2 PECs were
treated with PBS or gp96 for 4 h. IL-1b concentration in
supernatant was measured by ELISA. Data are from one
representative experiment of three to five independent
experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
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inflammasomes by gp96 is dependent on cellular K+ efflux.
Another damage-associated molecular pattern (DAMP), ATP,
acts through its own receptor P2X7 to also modulate K
+
channels (21). There are notable differences in the kinetics of
NLRP3 inflammasome activation by gp96 and these other
DAMPs, which may be physiologically relevant. The activa-
tion by gp96 could indicate that the kinetics of K+ efflux
induced by gp96 are slow and require chronic exposure of
APCs to this signal compared with the immediate K+ efflux
induced by ATP or nigericin. Alternatively, gp96 could ac-
tivate the NLRP3 inflammasomes indirectly, requiring other
endogenous signals.
The evolution of inflammasomes as an important detection
and response mediator to infection has been well charac-
terized (8). We show in this study that the release of IL-1b
in response to extracellular gp96 is dependent on NLRP3
inflammasomes. In contrast to other activators of the inflam-
masomes, gp96 also upregulates the inflammasome substrate
pro–IL-1b and components for the inflammasome NLRP3.
Thus, gp96 as a single entity simultaneously provides signals
for both arms necessary for IL-1b release. Multiple immu-
nogenic HSPs, including hsp90, hsp70, and calreticulin,
engage CD91 and cause the release of IL-1b from APCs
in vitro without additional stimuli (1). Activation of
inflammasomes by these HSPs remains to be formally tested.
Different inflammasome sensors may be involved with these
HSPs following other DAMPs, like dsDNA, which use
AIM2 inflammasomes (22). Robust inflammasome activa-
tion and activity is typically associated with some cell death,
including pyroptosis (8, 22). We show that gp96 triggered
some cell death, measured by annexin V/propidium iodide
positivity (Supplemental Fig. 2D), when compared with cell
death induced by LPS/nigericin. Cell death and IL-1b re-
lease was GD-dependent (Fig. 4E, Supplemental Fig. 2D).
Cell death was also induced in a GD-dependent manner
when cells were primed by LPS and stimulated with
200 mg/ml gp96 (Supplemental Fig. 2E). Interestingly,
IL-1b released under these conditions appeared not to rely
on GD (Supplemental Fig. 2F), possibly because of alter-
native release mechanisms triggered by LPS stimulation
and/or extended incubation times of this singular assay.
We show that extracellular gp96 released by cells in vivo
leads to plasma IL-1b and neutrophil extravasation. TNF-a,
another cytokine required for extravasation, is also released
from APCs stimulated with gp96 (1, 2). It is conceivable
that the HSP-mediated activation of inflammasomes may
be superseded or complemented during infection by stron-
ger pathogen-associated molecular pattern–mediated acti-
vation of inflammation; however, they nonetheless are likely
to contribute to the overall inflammatory picture. Sterile
or tissue damage–associated inflammation has long been
associated with various DAMPs. HSPs, the first DAMP, to
our knowledge, to be identified (23), are abundant intra-
cellular proteins, making their recognition by the immune
system a strong surrogate for detection of cellular aberrancy
in infectious and noninfectious conditions. Our studies
suggest novel therapies targeting CD91 would be expected
to be more effective at reducing inflammation than current
inhibitors such as MCC950 targeting NLRP3, because
CD91 is upstream of the inflammasomes and prior to signal
amplification.
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